United States Cancer Biomarker Market Opportunities, 2011 - 2021
As per the American Cancer Society estimates, the number of cancer cases in the United States is estimated to have stood at 1,658,370 in 2015. With growing incidence rate of cancer in the country, the demand for cancer biomarker for better diagnosis is also increasing at a robust pace. In the US, growing consumption of alcohol and high smoking prevalence coupled with poor dietary habits and sedentary lifestyle of the citizens is increasing cancer risk among the country’s population. Moreover, increasing government funding for cancer biomarker research, coupled with growing use of biomarkers in drug discovery development and clinical trials is further anticipated to fuel cancer biomarker market in the US over the next five years.
“United States Cancer Biomarker Market Opportunities, 2011 - 2021” report studies the market size and share of various segments and sub-segments of the cancer biomarker market in the United States during the period 2011 - 2021. In the study, the market has been categorized into five broader segments that include Immunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology and Bioinformatics.
The market dynamics section of the report elaborates the factors that are driving the market as well as the challenges inhibiting growth. The research study also includes insights of the key market trends, a detailed analysis of the changing competitive landscape, and revenue forecasts for each segment and sub-segment.
All this information is provided to assist the established market players and new entrants in taking their strategic decisions, thereby aiding them in strengthening their market position in a highly competitive cancer biomarker market in the United States.
“United States Cancer Biomarker Market Opportunities, 2011 - 2021” report elaborates the following aspects of cancer biomarker market in the United States:
The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with cancer biomarker manufacturers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.
“United States Cancer Biomarker Market Opportunities, 2011 - 2021” report studies the market size and share of various segments and sub-segments of the cancer biomarker market in the United States during the period 2011 - 2021. In the study, the market has been categorized into five broader segments that include Immunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology and Bioinformatics.
The market dynamics section of the report elaborates the factors that are driving the market as well as the challenges inhibiting growth. The research study also includes insights of the key market trends, a detailed analysis of the changing competitive landscape, and revenue forecasts for each segment and sub-segment.
All this information is provided to assist the established market players and new entrants in taking their strategic decisions, thereby aiding them in strengthening their market position in a highly competitive cancer biomarker market in the United States.
“United States Cancer Biomarker Market Opportunities, 2011 - 2021” report elaborates the following aspects of cancer biomarker market in the United States:
- United States Cancer Biomarker Market Size, Share & Forecast
- Segmental Analysis – By Profiling Technology (Immunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology & Bioinformatics), By Application (Drug Discovery and Development, Diagnosis, Prognostic, Risk Assessment & Others), By End User (Contract Research Organizations (CROs) and Drug Manufacturers & Healthcare Providers), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer & Others)
- Policy & Regulatory Landscape
- Changing Market Trends & Emerging Opportunities
- Competitive Landscape & Strategic Recommendations
- To identify the on-going trends and anticipated growth in the next five years
- To gain competitive knowledge of leading market players
- To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer’s specific needs
- What would be the segmental and regional growth trends in the United States cancer biomarker market in the coming years?
- What are the most important growth drivers and opportunities in the market?
- Which profiling technology is preferred the most?
- What strategies should market competitors employ to gain share in mature segments of the United States cancer biomarker market?
- What are the competitor profiles in this market and how do they compete for market share?
The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with cancer biomarker manufacturers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. ANALYST VIEW
4. GLOBAL CANCER BIOMARKER MARKET OVERVIEW
5. UNITED STATES CANCER BIOMARKER MARKET OVERVIEW
6. UNITED STATES CANCER BIOMARKER MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Profiling Technology (Immunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology & Bioinformatics)
6.2.2. By Application (Drug Discovery and Development, Diagnosis, Prognostics, Risk Assessment & Others)
6.2.3. By End User (Contract Research Organizations (CROs) and Drug Manufacturers, & Healthcare Providers)
6.2.4. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, & Others)
6.2.5. By Region
6.2.6. By Company
7. UNITED STATES CANCER BIOMARKER IMMUNOASSAY PROFILING TECHNOLOGY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Immunohistochemistry (IHC), Enzyme–linked Immunosorbent Assay (ELISA) & Flow Cytometry)
8. UNITED STATES CANCER BIOMARKER OMICS PROFILING TECHNOLOGY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Genomics, Proteomics & Others)
9. UNITED STATES CANCER BIOMARKER CYTOGENETIC PROFILING TECHNOLOGY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Fluorescent In-situ Hybridisation (FISH) & Others)
10. UNITED STATES CANCER BIOMARKER IMAGING PROFILING TECHNOLOGY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Computed Tomography (CT) & Others)
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS AND DEVELOPMENTS
12.1. Involvement of Biomarker in Personalised Medicine
12.2. Biomarkers as Surrogate Endpoints
12.3. New Product Developments
12.4. Prognostic and Predictive Biomarker Test for Breast Cancer
12.5. Product Enhancements
13. POLICY AND REGULATORY LANDSCAPE
14. UNITED STATES ECONOMIC PROFILE
15. COMPETITIVE LANDSCAPE
15.1. Abbott Laboratories
15.2. Affymetrix, Inc.
15.3. Roche Diagnostics Corporation
15.4. Illumina, Inc.
15.5. Hologic, Inc.
15.6. Merck & Co. Inc.
15.7. Agilent Technologies
15.8. Qiagen Sciences, Inc.
15.9. Becton, Dickinson and Company
15.10. Alere, Inc.
16. STRATEGIC RECOMMENDATION
2. RESEARCH METHODOLOGY
3. ANALYST VIEW
4. GLOBAL CANCER BIOMARKER MARKET OVERVIEW
5. UNITED STATES CANCER BIOMARKER MARKET OVERVIEW
6. UNITED STATES CANCER BIOMARKER MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Profiling Technology (Immunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology & Bioinformatics)
6.2.2. By Application (Drug Discovery and Development, Diagnosis, Prognostics, Risk Assessment & Others)
6.2.3. By End User (Contract Research Organizations (CROs) and Drug Manufacturers, & Healthcare Providers)
6.2.4. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, & Others)
6.2.5. By Region
6.2.6. By Company
7. UNITED STATES CANCER BIOMARKER IMMUNOASSAY PROFILING TECHNOLOGY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Immunohistochemistry (IHC), Enzyme–linked Immunosorbent Assay (ELISA) & Flow Cytometry)
8. UNITED STATES CANCER BIOMARKER OMICS PROFILING TECHNOLOGY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Genomics, Proteomics & Others)
9. UNITED STATES CANCER BIOMARKER CYTOGENETIC PROFILING TECHNOLOGY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Fluorescent In-situ Hybridisation (FISH) & Others)
10. UNITED STATES CANCER BIOMARKER IMAGING PROFILING TECHNOLOGY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Computed Tomography (CT) & Others)
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS AND DEVELOPMENTS
12.1. Involvement of Biomarker in Personalised Medicine
12.2. Biomarkers as Surrogate Endpoints
12.3. New Product Developments
12.4. Prognostic and Predictive Biomarker Test for Breast Cancer
12.5. Product Enhancements
13. POLICY AND REGULATORY LANDSCAPE
14. UNITED STATES ECONOMIC PROFILE
15. COMPETITIVE LANDSCAPE
15.1. Abbott Laboratories
15.2. Affymetrix, Inc.
15.3. Roche Diagnostics Corporation
15.4. Illumina, Inc.
15.5. Hologic, Inc.
15.6. Merck & Co. Inc.
15.7. Agilent Technologies
15.8. Qiagen Sciences, Inc.
15.9. Becton, Dickinson and Company
15.10. Alere, Inc.
16. STRATEGIC RECOMMENDATION
LIST OF TABLES
Table 1: United States Partial List of Cancer Biomarkers, By Cancer Type
Table 2: United States Partial List of Lung Cancer Biomarker, By Cancer Type, 2015
Table 3: United States Partial List of Metastatic Breast Cancer Biomarker, 2015
Table 4: United States Partial List of Colorectal Cancer Biomarker, 2015
Table 5: Southern United States Partial List of Clinical Research Companies, By State, 2015
Table 6: US Midwest Region Partial List of Clinical Research Companies, By State, 2015
Table 7: Partial List of Pharmacogenomic Cancer Biomarkers in Labelling of FDA Approved Drugs
Table 1: United States Partial List of Cancer Biomarkers, By Cancer Type
Table 2: United States Partial List of Lung Cancer Biomarker, By Cancer Type, 2015
Table 3: United States Partial List of Metastatic Breast Cancer Biomarker, 2015
Table 4: United States Partial List of Colorectal Cancer Biomarker, 2015
Table 5: Southern United States Partial List of Clinical Research Companies, By State, 2015
Table 6: US Midwest Region Partial List of Clinical Research Companies, By State, 2015
Table 7: Partial List of Pharmacogenomic Cancer Biomarkers in Labelling of FDA Approved Drugs
LIST OF FIGURES
Figure 1: United States Cancer Biomarker Market Size, By Value, 2011-2021F (USD Billion)
Figure 2: United States Cancer Biomarker Market Share, By Profiling Technology, By Value, 2011-2021F
Figure 3: United States Cancer Biomarker Market Share, By Application, By Value, 2011-2021F
Figure 4: United States Cancer Biomarker, By End User, By Value, 2011-2021F
Figure 5: United States Number of Contract Research Organisations (CROs), By Type, 2012
Figure 6: United States Cancer Biomarker, By Cancer Type, By Value, 2011-2021F
Figure 7: United States Estimated Number of New Lung & Bronchus Cancer Cases, By Sex, 2015 & 2016F
Figure 8: United States Estimated Number of New Breast Cancer Cases, By Sex, 2015 & 2016F
Figure 9: United States Female Breast Cancer Incidence Rate (per 100,000 population), By State, 2012
Figure 10: United States Cancer Biomarker Market Size, By Region, By Value, 2011-2015 (USD Billion)
Figure 11: United States Cancer Biomarker Market Size, By Region, By Value, 2016-2021 (USD Billion)
Figure 12: United States Cancer Biomarker Market Share, By Region, By Value, 2011-2021F
Figure 13: United States Cancer Biomarker Market Share, By Company, By Value, 2015 & 2021F
Figure 14: United States Cancer Biomarker Immunoassay Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
Figure 15: United States Cancer Biomarker Immunoassay Profiling Technology Market Share, By Type, By Value, 2011-2021F
Figure 16: United States Cancer Biomarker Omics Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
Figure 17: United States Cancer Biomarker Omics Profiling Technology Market Share, By Type, By Value, 2011-2021F
Figure 18: United States Cancer Biomarker Cytogenetic Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
Figure 19: United States Cancer Biomarker Cytogenetic Profiling Technology Market Share, By Type, By Value, 2011-2021F
Figure 20: United States Cancer Biomarker Imaging Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
Figure 21: United States Cancer Biomarker Imaging Profiling Technology Market Share, By Type, By Value, 2011-2021F
Figure 22: United States Cancer Incidence, By Cancer Type, 2012, 2015 & 2020F (Million)
Figure 1: United States Cancer Biomarker Market Size, By Value, 2011-2021F (USD Billion)
Figure 2: United States Cancer Biomarker Market Share, By Profiling Technology, By Value, 2011-2021F
Figure 3: United States Cancer Biomarker Market Share, By Application, By Value, 2011-2021F
Figure 4: United States Cancer Biomarker, By End User, By Value, 2011-2021F
Figure 5: United States Number of Contract Research Organisations (CROs), By Type, 2012
Figure 6: United States Cancer Biomarker, By Cancer Type, By Value, 2011-2021F
Figure 7: United States Estimated Number of New Lung & Bronchus Cancer Cases, By Sex, 2015 & 2016F
Figure 8: United States Estimated Number of New Breast Cancer Cases, By Sex, 2015 & 2016F
Figure 9: United States Female Breast Cancer Incidence Rate (per 100,000 population), By State, 2012
Figure 10: United States Cancer Biomarker Market Size, By Region, By Value, 2011-2015 (USD Billion)
Figure 11: United States Cancer Biomarker Market Size, By Region, By Value, 2016-2021 (USD Billion)
Figure 12: United States Cancer Biomarker Market Share, By Region, By Value, 2011-2021F
Figure 13: United States Cancer Biomarker Market Share, By Company, By Value, 2015 & 2021F
Figure 14: United States Cancer Biomarker Immunoassay Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
Figure 15: United States Cancer Biomarker Immunoassay Profiling Technology Market Share, By Type, By Value, 2011-2021F
Figure 16: United States Cancer Biomarker Omics Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
Figure 17: United States Cancer Biomarker Omics Profiling Technology Market Share, By Type, By Value, 2011-2021F
Figure 18: United States Cancer Biomarker Cytogenetic Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
Figure 19: United States Cancer Biomarker Cytogenetic Profiling Technology Market Share, By Type, By Value, 2011-2021F
Figure 20: United States Cancer Biomarker Imaging Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
Figure 21: United States Cancer Biomarker Imaging Profiling Technology Market Share, By Type, By Value, 2011-2021F
Figure 22: United States Cancer Incidence, By Cancer Type, 2012, 2015 & 2020F (Million)
